Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Revenue		$ 43,190	$ 48,926	$ 85,063	$ 86,573
Operating expenses		90,508	96,744	181,143	191,584
Adjusted EBITDA	[1]	(21,446)	(24,819)	(49,626)	(61,917)	[2]
Net loss		(46,248)	(47,811)	(93,781)	(105,511)
Net loss attributable to noncontrolling interest		26	1	52	2
Net loss attributable to Adaptive Biotechnologies Corporation		(46,222)	(47,810)	(93,729)	(105,509)
Interest and other income, net		(3,766)	(3,612)	(7,988)	(6,636)
Interest expense	[3]	2,696	3,605	5,689	7,136
Depreciation and amortization expense		5,003	5,653	10,217	11,076
Impairment of long-lived assets	[4]	7,205		7,205
Restructuring expense	[4]	680		1,724
Share-based compensation expense	[2]	12,958	17,345	27,256	32,016
Operating Segments | MRD
Segment Reporting Information [Line Items]
Revenue		35,284	25,882	67,910	47,309
Operating expenses		58,361	58,944	118,247	114,969
Adjusted EBITDA	[1]	(11,289)	(23,079)	(28,548)	(49,465)	[2]
Net loss		(23,077)	(33,063)	(50,337)	(67,660)
Net loss attributable to Adaptive Biotechnologies Corporation		(23,077)	(33,063)	(50,337)	(67,660)
Depreciation and amortization expense		2,604	2,267	5,305	4,323
Impairment of long-lived assets	[4]	2,819		2,819
Restructuring expense	[4]	561		1,028
Share-based compensation expense	[2]	5,804	7,717	12,637	13,872
Operating Segments | IM
Segment Reporting Information [Line Items]
Revenue		7,906	23,044	17,153	39,264
Operating expenses		26,133	30,681	49,974	62,353
Adjusted EBITDA	[1]	(7,033)	1,264	(13,960)	(6,163)	[2]
Net loss		(18,228)	(7,636)	(32,821)	(23,088)
Net loss attributable to Adaptive Biotechnologies Corporation		(18,228)	(7,636)	(32,821)	(23,088)
Depreciation and amortization expense		1,967	2,608	4,049	5,361
Impairment of long-lived assets	[4]	4,386		4,386
Restructuring expense	[4]	119		696
Share-based compensation expense	[2]	4,723	6,292	9,730	11,564
Unallocated Corporate
Segment Reporting Information [Line Items]
Operating expenses		6,014	7,119	12,922	14,262
Adjusted EBITDA	[1]	(3,124)	(3,004)	(7,118)	(6,289)	[2]
Net loss		(4,943)	(7,112)	(10,623)	(14,763)
Net loss attributable to noncontrolling interest		26	1	52	2
Net loss attributable to Adaptive Biotechnologies Corporation		(4,917)	(7,111)	(10,571)	(14,761)
Interest and other income, net		(3,766)	(3,612)	(7,988)	(6,636)
Interest expense	[3]	2,696	3,605	5,689	7,136
Depreciation and amortization expense		432	778	863	1,392
Share-based compensation expense	[2]	$ 2,431	$ 3,336	$ 4,889	$ 6,580

[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation for how it is calculated and used by management.

[2] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.

[3] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

[4] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.